| 2026 | | NOTCH4 as a driver of epithelial-mesenchymal transition, angiogenesis, and stromal remodeling in lung adenocarcinoma: integrated transcriptomic and protein-level validation
Translational lung cancer research, 15(3). : 55-55, 2026 | 고영화, 이현우, 한재호, 함석진 |
| 2026 | | Protocol Development for the Korean Survey for Cancer Survivorship and Preliminary Analysis of Employment Change’s Impact on Quality of Life and Psychological Health
Cancers, 18(2). : 219-219, 2026 | 이현우 |
| 2025 | | Real-world first-line outcomes of alectinib and brigatinib in anaplastic lymphoma kinase-positive non-small cell lung cancer: a nationwide South Korean cohort study using the health insurance review and assessment data
Translational lung cancer research, 14(11). : 4811-4823, 2025 | 박진희, 이현우 |
| 2025 | | Real-world treatment outcomes in South Korean patients with epidermal growth factor receptor-mutant non-small cell lung cancer
The Korean journal of internal medicine, 40(6). : 1029-1041, 2025 | 김태환, 안미선, 이현우, 최용원, 최진혁 |
| 2025 | | Identifying predictive markers of head and neck squamous cell carcinoma in an umbrella trial (KCSG HN 15-16 TRIUMPH trial)
ESMO open, 10(10). : 105772-105772, 2025 | 이현우 |
| 2025 | | Clinical Impact of TP53 Mutations in Patients with Head and Neck Cancer Who Were Treated with Targeted Therapies or Immunotherapy
Cancer research and treatment, 57(3). : 709-719, 2025 | 이현우 |
| 2025 | | Analysis of outcomes according to start timing of adjuvant chemotherapy in patients with gastric cancer: a retrospective nationwide cohort study
The oncologist, 30(6). : oyaf132-oyaf132, 2025 | 강석윤, 권민석, 김태환, 박범희, 안미선, 이현우, 최용원, 최진혁 |
| 2025 | | Senescence cell signature associated with poor prognosis, epithelial–mesenchymal transition, solid histology, and spread through air spaces in lung adenocarcinoma
GeroScience, 47(2). : 2423-2438, 2025 | 고영화, 이현우, 한재호, 함석진 |
| 2025 | | Target-Enhanced Whole-Genome Sequencing Shows Clinical Validity Equivalent to Commercially Available Targeted Oncology Panel
Cancer research and treatment, 57(2). : 350-361, 2025 | 권민석, 김석휘, 김장희, 김태환, 노진, 박준성, 안미선, 이현우, 최용원 |
| 2025 | | Immunosuppressive State May Lead to Brain Metastases in Lung Squamous Cell Carcinoma: Gene Expression and Immunohistochemical Analysis
Anticancer research, 45(2). : 525-534, 2025 | 고영화, 이현우, 한재호, 함석진 |
| 2024 | | Quality of life outcomes in terminal cancer patients attending regional cancer centers in South Korea: protocol for a prospective cohort study
BMC cancer, 24(1). : 1560-1560, 2024 | 이현우 |
| 2024 | | Safety of the Herbal Medicine SH003 in Patients With Solid Cancer: A Multi-Center, Single-Arm, Open-Label, Dose-Escalation Phase I Study
Integrative cancer therapies, 23. : 15347354241293451-15347354241293451, 2024 | 이현우 |
| 2024 | | Impact of senescence cell signature in patients with non-small cell carcinoma and melanoma receiving PD-L1/PD-1 inhibitors
Mechanisms of ageing and development, 222. : 111999-111999, 2024 | 고영화, 이현우, 한재호, 함석진 |
| 2024 | | Clinical application of whole-genome sequencing of solid tumors for precision oncology
Experimental & molecular medicine, 56(8). : 1856-1868, 2024 | 강석윤, 고영화, 곽규성, 권민석, 김석휘, 김선일, 김세혁, 김장희, 김재근, 김창우, 김철호, 김태환, 노성현, 노진, 노충균, 박지원, 박지은, 백수연, 손상용, 신승수, 안미선, 양민재, 유우식, 윤재성, 이기명, 이길호, 이다근, 이현우, 임선교, 장전엽, 정윤정, 조대성, 최용원, 최진혁, 하태양, 한상욱, 허지미, 허훈 |
| 2024 | | A Randomized, Multi-Center, Open Label Study to Compare the Safety and Efficacy between Afatinib Monotherapy and Combination Therapy with HAD-B1 for the Locally Advanced or Metastatic NSCLC Patients with EGFR Mutations
Integrative cancer therapies, 23. : 15347354241268231-15347354241268231, 2024 | 이현우 |
| 2024 | | Machine learning-driven prediction of brain metastasis in lung adenocarcinoma using miRNA profile and target gene pathway analysis of an mRNA dataset
Clinical & translational oncology, 26(9). : 2296-2308, 2024 | 고영화, 이현우, 한재호, 함석진 |
| 2024 | | Changes in the expression of cell interaction-related pathways during brain metastasis in lung adenocarcinoma: Gene expression and immunohistochemical analysis
Pathology, research and practice, 260. : 155375-155375, 2024 | 고영화, 이현우, 한재호, 함석진 |
| 2024 | | The impact of CDCA5 expression on the immune microenvironment and its potential utility as a biomarker for PD-L1/PD-1 inhibitors in lung adenocarcinoma | 고영화, 이현우, 한재호, 함석진 |
| 2024 | | Prediction of Responsiveness to PD-L1/PD-1 Inhibitors Using miRNA Profiles Associated With PD-L1 Expression in Lung Adenocarcinoma and Squamous Cell Carcinoma
Anticancer research, 44(5). : 2081-2089, 2024 | 고영화, 이현우, 한재호, 함석진 |
| 2024 | | Real-world treatment patterns and clinical outcomes in patients with stage III NSCLC in Korea: The KINDLE study
Cancer medicine, 13(7). : e7174-e7174, 2024 | 이현우 |
| 2024 | | Impact of PIK3CA and cell cycle pathway genetic alterations on durvalumab efficacy in patients with head and neck squamous cell carcinoma: Post hoc analysis of TRIUMPH study
Oral oncology, 151. : 106739-106739, 2024 | 이현우 |
| 2024 | | Differential efficacy of tyrosine kinase inhibitors according to the types of EGFR mutations and agents in non-small cell lung cancer: a real-world study
BMC cancer, 24(1). : 70-70, 2024 | 강석윤, 고영화, 김태환, 신승수, 안미선, 이현우, 최용원, 최진혁 |
| 2024 | | Second-line chemoimmunotherapy with nivolumab and paclitaxel in immune-related biomarker-enriched advanced gastric cancer: a multicenter phase Ib/II study
Gastric cancer, 27(1). : 118-130, 2024 | 이현우 |
| 2024 | | Open-Label, Multicenter, Randomized, Biomarker-Integrated Umbrella Trial for Second-Line Treatment of Advanced Gastric Cancer: K-Umbrella Gastric Cancer Study
Journal of clinical oncology, 42(3). : 348-357, 2024 | 이현우 |
| 2024 | | A Phase II Trial of Nintedanib in Patients with Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma: In-Depth Analysis of Nintedanib Arm from the KCSG HN 15-16 TRIUMPH Trial
Cancer research and treatment, 56(1). : 37-47, 2024 | 이현우 |
| 2023 | | Thromboembolic events in patients who received adjuvant chemotherapy for gastric cancer: a single-center retrospective study
Gastric cancer, 26(6). : 1012-1019, 2023 | 강석윤, 권민석, 김태환, 손상용, 신승수, 안미선, 이현우, 최용원, 최진혁, 한상욱, 허훈 |
| 2023 | | Immune profiles according to EGFR mutant subtypes and correlation with PD-1/PD-L1 inhibitor therapies in lung adenocarcinoma
Frontiers in immunology, 14. : 1137880-1137880, 2023 | 고영화, 박범희, 이현우, 한재호, 함석진 |
| 2023 | | Intrinsic and Extrinsic Transcriptional Profiles That Affect the Clinical Response to PD-1 Inhibitors in Patients with Non–Small Cell Lung Cancer
Cancers, 15(1). : 197-197, 2023 | 고영화, 변혜은, 이현우, 한재호, 함석진 |
| 2022 | | Totality outcome of afatinib sequential treatment in patients with EGFR mutation-positive non-small cell lung cancer in South Korea (TOAST): Korean Cancer Study Group (KCSG) LU-19-22
Translational lung cancer research, 11(7). : 1369-1379, 2022 | 이현우 |
| 2022 | | Prognostic and predictive value of YTHDF1 and YTHDF2 and their correlation with tumor-infiltrating immune cells in non-small cell carcinoma
Frontiers in oncology, 12. : 996634-996634, 2022 | 고영화, 이현우, 한재호, 함석진 |
| 2022 | | The efficacy of EGFR-tyrosine kinase inhibitor in non-small cell lung cancer patients with synchronous brain metastasis: a real-world study
The Korean journal of internal medicine, 37(2). : 434-443, 2022 | 강석윤, 김세혁, 노오규, 노태훈, 신승수, 안미선, 오영택, 이현우, 최용원, 최진혁 |
| 2022 | | Erratum: Analysis of thromboembolic events in head and neck cancer patients who underwent concurrent chemoradiotherapy with cisplatin
The Korean journal of internal medicine, 37(6). : 1269-1269, 2022 | 강석윤, 김철호, 김태환, 신승수, 신유섭, 안미선, 오영택, 이현우, 장전엽, 최용원, 최진혁, 허재성 |
| 2022 | | Analysis of thromboembolic events in head and neck cancer patients who underwent concurrent chemoradiotherapy with cisplatin
The Korean journal of internal medicine, 37(3). : 653-659, 2022 | 강석윤, 김철호, 김태환, 신승수, 신유섭, 안미선, 오영택, 이현우, 장전엽, 최용원, 최진혁, 허재성 |
| 2022 | | Analysis of treatment outcomes according to the cycles of adjuvant chemotherapy in gastric cancer: a retrospective nationwide cohort study
BMC cancer, 22(1). : 948-948, 2022 | 강석윤, 김태환, 안미선, 이현우, 최용원, 최진혁 |
| 2022 | | Analysis of thromboembolic events in patients with non-small cell lung cancer who received adjuvant chemotherapy: single-center real-world data
Scientific reports, 12(1). : 7646-7646, 2022 | 강석윤, 김태환, 신승수, 안미선, 이현우, 최용원, 최진혁 |
| 2021 | | Efficacy of concurrent chemoradiotherapy for patients with limited-disease small-cell lung cancer: a retrospective, nationwide, population-based cohort study
BMC cancer, 21(1). : 340-340, 2021 | 이현우 |
| 2021 | | Trastuzumab-based palliative chemotherapy for HER2-positive gastric cancer: a single-center real-world data
BMC cancer, 21(1). : 325-325, 2021 | 강석윤, 김태환, 신승수, 안미선, 이현우, 조헌도, 최용원, 최진혁 |
| 2021 | | Early removal of central venous catheter may not impact the in-hospital mortality in patients with acute leukemia
Annals of hematology, 100(11). : 2825-2830, 2021 | 강석윤, 김태환, 박준성, 안미선, 이현우, 정성현, 최용원, 최윤석, 최진혁 |
| 2021 | | Modified FOLFIRINOX versus S-1 as second-line chemotherapy in gemcitabine-failed metastatic pancreatic cancer patients: A randomised controlled trial (MPACA-3)
European journal of cancer (Oxford, England : 1990), 157. : 21-30, 2021 | 이현우 |
| 2021 | | Tumor nonimmune-microenvironment-related gene expression signature predicts brain metastasis in lung adenocarcinoma patients after surgery: A machine learning approach using gene expression profiling
Cancers, 13(17). : 4468-4468, 2021 | 고영화, 이현우, 한재호, 함석진 |
| 2021 | | Treatment Outcomes of 9,994 Patients With Extensive-Disease Small-Cell Lung Cancer From a Retrospective Nationwide Population-Based Cohort in the Korean HIRA Database
Frontiers in oncology, 11. : 546672-546672, 2021 | 이현우 |
| 2021 | | An immune-related gene expression signature predicts brain metastasis in lung adenocarcinoma patients after surgery: Gene expression profile and immunohistochemical analyses
Translational lung cancer research, 10(2). : 802-814, 2021 | 고영화, 이현우, 한재호, 함석진 |
| 2020 | | DeepBTS: Prediction of recurrence-free survival of non-small cell lung cancer using time-binned deep neural network
Cancer research, 80(16S). : 2091-2091, 2020 | 이현우 |
| 2020 | | Ramosetron versus Palonosetron in Combination with Aprepitant and Dexamethasone for the Control of Highly-Emetogenic Chemotherapy-Induced Nausea and Vomiting
Cancer research and treatment, 52(3). : 907-916, 2020 | 이현우 |
| 2020 | | HIP1R Expression and Its Association with PD-1 Pathway Blockade Response in Refractory Advanced NonSmall Cell Lung Cancer: A Gene Set Enrichment Analysis
Journal of clinical medicine, 9(5). : 1425-1425, 2020 | 고영화, 이현우, 한재호, 함석진 |
| 2020 | | Prognostic Value of CD200R1 mRNA Expression in Head and Neck Squamous Cell Carcinoma
Cancers, 12(7). : 1777-1777, 2020 | 이현우 |
| 2020 | | Combination versus single-agent as palliative chemotherapy for gastric cancer
BMC cancer, 20(1). : 167-167, 2020 | 강석윤, 박준성, 신승수, 안미선, 이현우, 정성현, 최용원, 최진혁 |
| 2020 | | A Neuropilin-1 Antagonist Exerts Antitumor Immunity by Inhibiting the Suppressive Function of Intratumoral Regulatory T Cells
Cancer immunology research, 8(1). : 46-56, 2020 | 김철호, 이현우, 정근옥, 함석진 |
| 2020 | | DeepBTS: Prediction of Recurrence-free Survival of Non-small Cell Lung Cancer Using a Time-binned Deep Neural Network
Scientific reports, 10(1). : 1952-1952, 2020 | 이현우 |
| 2019 | | Capecitabine plus Oxaliplatin as a Second-Line Therapy for Advanced Biliary Tract Cancers: A Multicenter, Open-Label, Phase II Trial
Journal of Cancer, 10(25). : 6185-6190, 2019 | 이현우 |
